GREY:ATBPF - Post Discussion
Post by
Duster340 on Nov 25, 2022 9:33am
Price Target $2 us
Antibe Therapeutics (ATBPF)
In a report released today, Stefan Quenneville from Echelon Wealth Partners maintained a Buy rating on Antibe Therapeutics, with a price target of C$2.00. The company’s shares closed last Monday at $0.36, close to its 52-week low of $0.35.
Be the first to comment on this post